RDNT
RadNet, Inc.
Medical - Diagnostics & Research
Market Cap$4.45B
5Y Perf.+193.8%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
RDNT vs AORT vs NVCR vs NNOX vs SYK
Revenue, margins, valuation, and 5-year total return — side by side.
AORT
Artivion, Inc.
Medical - Devices
Market Cap$1.72B
5Y Perf.+49.9%
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-90.3%
NNOX
Nano-X Imaging Ltd.
Medical - Devices
Market Cap$115M
5Y Perf.-96.1%
SYK
Stryker Corporation
Medical - Devices
Market Cap$112.69B
5Y Perf.+20.1%
RDNT vs AORT vs NVCR vs NNOX vs SYK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RDNT | AORT | NVCR | NNOX | SYK |
|---|---|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices | Medical - Devices |
| Market Cap | $4.45B | $1.72B | $1.92B | $115M | $112.69B |
| Revenue (TTM) | $2.04B | $459M | $674M | $12M | $25.12B |
| Net Income (TTM) | $47M | $12M | $-173M | $-56M | $3.25B |
| Gross Margin | 11.2% | 63.8% | 75.2% | -98.8% | 63.5% |
| Operating Margin | 3.0% | 7.4% | -27.2% | -469.7% | 22.4% |
| Forward P/E | 91.8x | 98.7x | — | — | 19.6x |
| Total Debt | $1.86B | $292M | $290M | $7M | $14.86B |
| Cash & Equiv. | $767M | $65M | $103M | $39M | $4.01B |
RDNT vs AORT vs NVCR vs NNOX vs SYK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RDNT
AORT
NVCR
NNOX
SYK
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| RadNet, Inc. (RDNT) | 100 | 293.8 | +193.8% |
| Artivion, Inc. (AORT) | 100 | 149.9 | +49.9% |
| NovoCure Limited (NVCR) | 100 | 9.7 | -90.3% |
| Nano-X Imaging Ltd. (NNOX) | 100 | 3.9 | -96.1% |
| Stryker Corporation (SYK) | 100 | 120.1 | +20.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RDNT vs AORT vs NVCR vs NNOX vs SYK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SYK leads in 5 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Artivion, Inc. is the stronger pick specifically for recent price momentum and sentiment. NNOX also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
RDNT
RadNet, Inc.
The Long-Run Compounder
RDNT is the clearest fit if your priority is long-term compounding.
- 9.5% 10Y total return vs AORT's 188.9%
Best for: long-term compounding
AORT
Artivion, Inc.
The Defensive Pick
AORT is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 0.63, Low D/E 65.2%, current ratio 2.99x
- Beta 0.63, current ratio 2.99x
- +24.7% vs NNOX's -64.4%
Best for: sleep-well-at-night and defensive
NVCR
NovoCure Limited
The Healthcare Pick
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
Best for: healthcare exposure
NNOX
Nano-X Imaging Ltd.
The Growth Play
NNOX ranks third and is worth considering specifically for growth exposure.
- Rev growth 13.9%, EPS growth 15.7%, 3Y rev CAGR 105.3%
- 13.9% revenue growth vs NVCR's 8.3%
Best for: growth exposure
SYK
Stryker Corporation
The Income Pick
SYK carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 34 yrs, beta 0.55, yield 1.1%
- Better valuation composite
- 12.9% margin vs NNOX's -452.8%
- Beta 0.55 vs NVCR's 2.20, lower leverage
Best for: income & stability
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NNOX | 13.9% revenue growth vs NVCR's 8.3% |
| Value | SYK | Better valuation composite |
| Quality / Margins | SYK | 12.9% margin vs NNOX's -452.8% |
| Stability / Safety | SYK | Beta 0.55 vs NVCR's 2.20, lower leverage |
| Dividends | SYK | 1.1% yield; 34-year raise streak; the other 4 pay no meaningful dividend |
| Momentum (1Y) | AORT | +24.7% vs NNOX's -64.4% |
| Efficiency (ROA) | SYK | 6.9% ROA vs NNOX's -31.6%, ROIC 11.4% vs -27.9% |
RDNT vs AORT vs NVCR vs NNOX vs SYK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
Segment breakdown not available.
Segment breakdown not available.
FY 2025
RDNT vs AORT vs NVCR vs NNOX vs SYK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSYKLAGGINGNNOX
Who Leads Where
SYK leads in 4 of 6 categories
AORT leads 1 • RDNT leads 0 • NVCR leads 0 • NNOX leads 0 • 1 tied
Explore the data ↓NNOXNano-X Imaging Ltd.
0leads
NVCRNovoCure Limited
0leads
RDNTRadNet, Inc.
0leads
AORTArtivion, Inc.
1leads
SYKStryker Corporation
4leads
6 Total Categories
CATEGORYLEADERvs AORTvs RDNTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SYK3/6
Valuation MetricsMultiples, price ratios, and targets
SYK3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SYK6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
AORT3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
SYK1/1
Income & Cash Flow (Last 12 Months)
SYK leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SYK is the larger business by revenue, generating $25.1B annually — 2041.6x NNOX's $12M. SYK is the more profitable business, keeping 12.9% of every revenue dollar as net income compared to NNOX's -4.5%. On growth, AORT holds the edge at +17.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | RDNTRadNet, Inc. | AORTArtivion, Inc. | NVCRNovoCure Limited | NNOXNano-X Imaging Lt… | SYKStryker Corporati… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.0B | $459M | $674M | $12M | $25.1B |
| EBITDAEarnings before interest/tax | $214M | $51M | -$165M | -$46M | $6.3B |
| Net IncomeAfter-tax profit | $47M | $12M | -$173M | -$56M | $3.2B |
| Free Cash FlowCash after capex | -$178M | $13M | -$48M | -$47M | $4.3B |
| Gross MarginGross profit ÷ Revenue | +11.2% | +63.8% | +75.2% | -98.8% | +63.5% |
| Operating MarginEBIT ÷ Revenue | +3.0% | +7.4% | -27.2% | -4.7% | +22.4% |
| Net MarginNet income ÷ Revenue | +2.3% | +2.5% | -25.7% | -4.5% | +12.9% |
| FCF MarginFCF ÷ Revenue | -8.7% | +2.8% | -7.1% | -3.8% | +17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +14.8% | +17.5% | +12.3% | +13.7% | +11.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -114.1% | +3.5% | -100.0% | +8.7% | +56.0% |
SYK leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
SYK leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 35.0x trailing earnings, SYK trades at a 79% valuation discount to AORT's 168.5x P/E. On an enterprise value basis, SYK's 20.3x EV/EBITDA is more attractive than AORT's 39.5x.
| Metric | RDNTRadNet, Inc. | AORTArtivion, Inc. | NVCRNovoCure Limited | NNOXNano-X Imaging Lt… | SYKStryker Corporati… |
|---|---|---|---|---|---|
| Market CapShares × price | $4.5B | $1.7B | $1.9B | $115M | $112.7B |
| Enterprise ValueMkt cap + debt − cash | $5.5B | $1.9B | $2.1B | $83M | $123.5B |
| Trailing P/EPrice ÷ TTM EPS | -230.00x | 168.52x | -13.80x | -1.93x | 35.03x |
| Forward P/EPrice ÷ next-FY EPS est. | 91.75x | 98.69x | — | — | 19.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 2.36x |
| EV / EBITDAEnterprise value multiple | 25.88x | 39.50x | — | — | 20.31x |
| Price / SalesMarket cap ÷ Revenue | 2.18x | 3.89x | 2.92x | 10.20x | 4.49x |
| Price / BookPrice ÷ Book value/share | 3.19x | 3.72x | 5.51x | 0.55x | 5.02x |
| Price / FCFMarket cap ÷ FCF | 52.01x | — | — | — | 26.31x |
SYK leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
SYK leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-51 for NVCR. NNOX carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to RDNT's 1.37x. On the Piotroski fundamental quality scale (0–9), AORT scores 6/9 vs NNOX's 4/9, reflecting solid financial health.
| Metric | RDNTRadNet, Inc. | AORTArtivion, Inc. | NVCRNovoCure Limited | NNOXNano-X Imaging Lt… | SYKStryker Corporati… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +3.8% | +2.7% | -50.8% | -35.5% | +15.0% |
| ROA (TTM)Return on assets | +1.3% | +1.3% | -16.5% | -31.6% | +6.9% |
| ROICReturn on invested capital | +2.0% | +3.2% | -16.4% | -27.9% | +11.4% |
| ROCEReturn on capital employed | +2.1% | +3.6% | -28.9% | -28.4% | +13.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 5 | 4 | 6 |
| Debt / EquityFinancial leverage | 1.37x | 0.65x | 0.85x | 0.04x | 0.66x |
| Net DebtTotal debt minus cash | $1.1B | $227M | $187M | -$32M | $10.8B |
| Cash & Equiv.Liquid assets | $767M | $65M | $103M | $39M | $4.0B |
| Total DebtShort + long-term debt | $1.9B | $292M | $290M | $7M | $14.9B |
| Interest CoverageEBIT ÷ Interest expense | 1.46x | 1.28x | -96.80x | -379.29x | 6.72x |
SYK leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
AORT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RDNT five years ago would be worth $24,710 today (with dividends reinvested), compared to $605 for NNOX. Over the past 12 months, AORT leads with a +24.7% total return vs NNOX's -64.4%. The 3-year compound annual growth rate (CAGR) favors AORT at 34.3% vs NNOX's -52.4% — a key indicator of consistent wealth creation.
| Metric | RDNTRadNet, Inc. | AORTArtivion, Inc. | NVCRNovoCure Limited | NNOXNano-X Imaging Lt… | SYKStryker Corporati… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -19.0% | -20.4% | +28.3% | -37.8% | -15.2% |
| 1-Year ReturnPast 12 months | +4.6% | +24.7% | +1.1% | -64.4% | -22.5% |
| 3-Year ReturnCumulative with dividends | +100.0% | +142.2% | -75.7% | -89.2% | +5.5% |
| 5-Year ReturnCumulative with dividends | +147.1% | +15.4% | -91.3% | -93.9% | +21.5% |
| 10-Year ReturnCumulative with dividends | +947.4% | +188.9% | +30.3% | -96.1% | +187.1% |
| CAGR (3Y)Annualised 3-year return | +26.0% | +34.3% | -37.6% | -52.4% | +1.8% |
AORT leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NVCR and SYK each lead in 1 of 2 comparable metrics.
Risk & Volatility
SYK is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs NNOX's 30.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RDNTRadNet, Inc. | AORTArtivion, Inc. | NVCRNovoCure Limited | NNOXNano-X Imaging Lt… | SYKStryker Corporati… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.43x | 0.63x | 2.20x | 1.86x | 0.55x |
| 52-Week HighHighest price in past year | $85.84 | $48.25 | $20.06 | $5.86 | $404.87 |
| 52-Week LowLowest price in past year | $50.76 | $26.84 | $9.82 | $1.66 | $289.91 |
| % of 52W HighCurrent price vs 52-week peak | +67.0% | +73.3% | +83.9% | +30.0% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 42.1 | 69.8 | 38.5 | 24.3 |
| Avg Volume (50D)Average daily shares traded | 822K | 385K | 1.5M | 1.4M | 2.1M |
Evenly matched — NVCR and SYK each lead in 1 of 2 comparable metrics.
Analyst Outlook
SYK leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: RDNT as "Buy", AORT as "Buy", NVCR as "Buy", NNOX as "Buy", SYK as "Buy". Consensus price targets imply 922.7% upside for NNOX (target: $18) vs 37.2% for SYK (target: $404). SYK is the only dividend payer here at 1.14% yield — a key consideration for income-focused portfolios.
| Metric | RDNTRadNet, Inc. | AORTArtivion, Inc. | NVCRNovoCure Limited | NNOXNano-X Imaging Lt… | SYKStryker Corporati… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $92.00 | $52.00 | $33.50 | $18.00 | $403.69 |
| # AnalystsCovering analysts | 11 | 12 | 15 | 5 | 50 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +1.1% |
| Dividend StreakConsecutive years of raises | 0 | 4 | — | — | 34 |
| Dividend / ShareAnnual DPS | — | — | — | — | $3.36 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
SYK leads this category, winning 1 of 1 comparable metric.
Key Takeaway
SYK leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). AORT leads in 1 (Total Returns). 1 tied.
Best OverallStryker Corporation (SYK)Leads 4 of 6 categories
Loading custom metrics...
RDNT vs AORT vs NVCR vs NNOX vs SYK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RDNT or AORT or NVCR or NNOX or SYK a better buy right now?
For growth investors, Nano-X Imaging Ltd.
(NNOX) is the stronger pick with 13. 9% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Stryker Corporation (SYK) offers the better valuation at 35. 0x trailing P/E (19. 6x forward), making it the more compelling value choice. Analysts rate RadNet, Inc. (RDNT) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RDNT or AORT or NVCR or NNOX or SYK?
On trailing P/E, Stryker Corporation (SYK) is the cheapest at 35.
0x versus Artivion, Inc. at 168. 5x. On forward P/E, Stryker Corporation is actually cheaper at 19. 6x.
03Which is the better long-term investment — RDNT or AORT or NVCR or NNOX or SYK?
Over the past 5 years, RadNet, Inc.
(RDNT) delivered a total return of +147. 1%, compared to -93. 9% for Nano-X Imaging Ltd. (NNOX). Over 10 years, the gap is even starker: RDNT returned +947. 4% versus NNOX's -96. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RDNT or AORT or NVCR or NNOX or SYK?
By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.
55β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 303% more volatile than SYK relative to the S&P 500. On balance sheet safety, Nano-X Imaging Ltd. (NNOX) carries a lower debt/equity ratio of 4% versus 137% for RadNet, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — RDNT or AORT or NVCR or NNOX or SYK?
By revenue growth (latest reported year), Nano-X Imaging Ltd.
(NNOX) is pulling ahead at 13. 9% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Artivion, Inc. grew EPS 165. 6% year-over-year, compared to -768. 4% for RadNet, Inc.. Over a 3-year CAGR, NNOX leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RDNT or AORT or NVCR or NNOX or SYK?
Stryker Corporation (SYK) is the more profitable company, earning 12.
9% net margin versus -474. 3% for Nano-X Imaging Ltd. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -502. 9% for NNOX. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RDNT or AORT or NVCR or NNOX or SYK more undervalued right now?
On forward earnings alone, Stryker Corporation (SYK) trades at 19.
6x forward P/E versus 98. 7x for Artivion, Inc. — 79. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NNOX: 922. 7% to $18. 00.
08Which pays a better dividend — RDNT or AORT or NVCR or NNOX or SYK?
In this comparison, SYK (1.
1% yield) pays a dividend. RDNT, AORT, NVCR, NNOX do not pay a meaningful dividend and should not be held primarily for income.
09Is RDNT or AORT or NVCR or NNOX or SYK better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
55), 1. 1% yield, +187. 1% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RDNT and AORT and NVCR and NNOX and SYK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
SYK pays a dividend while RDNT, AORT, NVCR, NNOX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(RDNT: 14.8% · AORT: 17.5%)Net Margin>
%
(RDNT: 2.3% · AORT: 2.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.